Morilyte™ works
without
exerting any pharmacological, immunological or metabolic action or effects on the human body

Following oral administration, Morilyte™ is not absorbed from the gastrointestinal tract and is generally regarded as non-toxic and non-irritant material.

All clinical studies consistently demonstrated that the diomectite contained in Morilyte™ has a good safety profile and is well tolerated. No serious adverse effects related to the treatment were observed in clinical studies, and no sign of toxicity was observed in the acute and chronic toxicological animal studies. Morilyte™ passed all the biocompatibility tests carried out according to EN ISO 10993,  which include the acute systemic toxicity, intracutaneous reactivity, sensitisation and cytotoxicity tests.

Morilyte™ protects the GI mucosa and entraps viruses, toxins and bacteria without any pharmacological, immunological or metabolic action or effects on the human body. As a result of this non-systemic mechanism of action products made with Morilyte™ are certified as a Class IIa medical device under the Medical Device Directive 93/42/EEC.

 


* What is a Medical Device?

A medical device is amongst others defined as any article, whether used alone or in combination, intended by the manufacturer to be used for human beings for the purpose of: prevention, monitoring, treatment or alleviation of disease and which achieves its principal intended action in or on the human body, not through any pharmacological, immunological or metabolic means, but which may be assisted in its function by such means.

 

 

 

 

Previous | Next

 
Copyright © 2013 by InQpharm Group. All rights reserved. Last updated: July 2013 | ID: MM/TM/EN/13/002
Morilyte and InQpharm are trademarks of the InQpharm group of companies.